ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?

被引：1
|
作者：
Ushida, Yuta [1 ]
Inoue, Yosuke [1 ]
Oba, Atsushi [1 ]
Mie, Takafumi [1 ]
Ito, Hiromichi [1 ]
Ono, Yoshihiro [1 ]
Sato, Takafumi [1 ]
Ozaka, Masato [1 ]
Sasaki, Takashi [1 ]
Saiura, Akio [1 ,2 ]
Sasahira, Naoki [1 ]
Takahashi, Yu [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Surg, Tokyo, Japan
[2] Juntendo Univ Hosp, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan
来源：
ANNALS OF SURGICAL ONCOLOGY | 2022年 / 29卷 / 08期
关键词：
D O I：
10.1245/s10434-022-11621-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5051 / 5052
页数：2
相关论文
共 48 条
  • [21] Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival
    Pacheco-Barcia, V.
    France, T.
    Zogopoulos, G.
    Bouganim, N.
    Donnay, O.
    Alcindor, T.
    Mondejar Solis, R.
    Guo, K.
    Martin, E.
    Colomer, R.
    Asselah, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study (Apr, 10.1245/S10434-022-11741-8, 2022)
    Ushida, Yuta
    Inoue, Yosuke
    Oba, Atsushi
    Mie, Takafumi
    Ito, Hiromichi
    Ono, Yoshihiro
    Sato, Takafumi
    Ozaka, Masato
    Sasaki, Takashi
    Saiura, Akio
    Sasahira, Naoki
    Takahashi, Yu
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (09) : 6047 - 6047
  • [23] Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report
    Yokota, Tetsuo
    Takano, Shigetsugu
    Yoshitomi, Hideyuki
    Kagawa, Shingo
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Kuboki, Satoshi
    Suzuki, Daisuke
    Sakai, Nozomu
    Nojima, Hiroyuki
    Mishima, Takashi
    Nakadai, Eri
    Ohtsuka, Masayuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (04) : 419 - 424
  • [24] Clinical outcome of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer.
    Watanabe, Kazuo
    Hashimoto, Yusuke
    Umemoto, Kumiko
    Takahashi, Hideaki
    Sasaki, Mitsuhito
    Imaoka, Hiroshi
    Ohno, Izumi
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [25] A Case of Unresectable Pancreatic Cancer With BRCA1 Gene Mutation Effectively Worked by Modified FOLFIRINOX After Gemcitabine Plus Nab-Paclitaxel Refractory
    Maesono, T.
    Nishioka, M.
    Sugiura, C.
    Kawai, K.
    Okano, N.
    Kobayashi, T.
    Nagashima, F.
    Shibahara, J.
    Sakamoto, Y.
    Furuse, Y.
    PANCREAS, 2019, 48 (10) : 1484 - 1484
  • [26] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [27] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
  • [28] Outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) in initially unresectable locally advanced pancreatic cancer (uLAPC): A population-based study.
    Chan, Kelvin K.
    Guo, Helen
    Beca, Jaclyn Marie
    Redmond-Misner, Ruby
    Isaranuwatchai, Wanrudee
    Qiao, Lucy
    Earle, Craig
    Berry, Scott R.
    Biagi, James Joseph
    Welch, Stephen
    Meyers, Brandon
    Mittmann, Nicole
    Coburn, Natalie
    Pardhan, Aliya
    Arias, Jessica
    Gavura, Scott
    Kennedy, Erin Diane
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [29] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [30] Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis
    Hayuka, Kotone
    Okuyama, Hiroyuki
    Murakami, Akitsu
    Okita, Yoshihiro
    Nishiuchi, Takamasa
    Okano, Keiichi
    Suzuki, Yasuyuki
    Tsuji, Akihito
    CHEMOTHERAPY, 2021, 66 (03) : 58 - 64
12345